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2. INTRODUCTION AND OBJECTIVES 
Most stakeholders in the health field want to minimize the burden of illness and have patients 
maintain their ability to work and enjoy an active, independent life (functional health status), receive 
the right care (appropriateness) at the right time (access) in a satisfying and efficient manner; and 
this with available resources avoiding unnecessary costs.1 Growing evidence, however, suggests that 
the daily practice of care does not correspond to the standards that the medical profession itself 
puts forward. To improve care and to realise potential medical and economical benefits, 
policymakers are looking for methods to measure and benchmark the performance of health care 
systems2. 
In this context one of the key issues is quality, and in particular medial quality. Medical quality 
has been controversially discussed in Swiss and international health policy during the last few years 
and is becoming more important, in view of limited and possible diminishing resources for health 
care in the future3. Service providers such as the pharmaceutical industry and the medical 
community4, payers such as insurers5, health authorities6 and the users7 have an interest in 
demonstrating efficiency and efficacy of medical care and treatment methods. The legal bases are 
the Swiss constitution and the federal law on health insurance (KVG). In art.32 of the KVG it is 
clearly mentioned that the medical services have to prove their effectiveness, efficacy and efficiency. 
In article 43, paragraph 6 of the same law the dimension of quality is added by defining the 
responsibilities of the health authorities and the contractual partners in the production of medical 
services that are effective and the best quality possible at the lowest cost possible. Nevertheless, 
concise and applicable medical quality criteria have been scarcely developed and hardly put into 
practice. The Swiss Medical Association (FMH) and its medical expert commissions recommend 
the establishment and use of best practice guidelines but neither controls neither its applications 
nor the outcomes.8 
This debate applies equally to the treatment of end stage renal disease (ESRD) that requires 
renal replacement therapy. This paper will only analyse dialysis as it is the major renal replacement 
therapy in Switzerland. Several guidelines exist on the national and international level, the most 
important being the American K/DOQI, the British guideline of the UK Renal Association and 
the European best practice guidelines.9 In Switzerland however, the national society for nephrology 
has not yet developed a national guideline nor does it clearly recommend one of the existing ones.10 
But why is the question of quality in dialysis treatment so important? Firstly, there are legal 
obligations which are set out in article 43 and 58 of the federal law on health insurance to which the 
different parties in health care are bound to produce the best quality possible at the lowest costs 
possible. There are remaining questions about the demand for this type of treatment, the economic 
impact and the feasibility of implementation of quality control measures. In view of an ageing 
population, the demand for dialysis treatment will soar in the coming years; in the US, the number 
of patients on dialysis is expected to double within the next decade11. In Switzerland the number of 
patients on dialysis and insured via the Swiss Federation for common tasks of the health insurances 
(SVK) increased by 11.8 % from 2003 to 200412. This reflects a trend across Europe13 which will 
continue with an ageing population and a higher incidence in ESRD. Patients receiving this type of 
treatment are, in general, chronically ill, nearly all on life-long treatment, have multiple associated 
pathologies and suffer from a high annual mortality (in the US still around 20 %) despite 
continuous advances14. Subsequently, they are in permanent medial care and at all times available to 
participate in quality improvement measures. Their general health state and their living quality 
depend essentially on the quality of the dialysis treatment which may encourage patients to 
participate actively in quality improvement, even accepting fundamental changes in dialysis 
patterns15. 
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Despite the fact that in article 4 and 5 of the contract between provider (in- and outpatient 
facilities) and insurer (here SVK), clear reference is given to the principle of economicity and 
quality. Nationally accepted quality criteria for dialysis treatment do not yet exist. Other countries 
such as the United States (Medicare)16 and Germany (QiN-system)17 have gathered positive 
experience with their respective quality systems.  
The SVK alone has access to data of 5.9 million people via their affiliated health insurance 
companies, meaning that in 2004 an estimated 80% of the patients receiving dialysis treatment were 
registered by the SVK, totalling 2773 patients.18 This concentration of data and negotiation partners 
may constitute a positive factor for the implementation of quality assessment. 
3730 dialysis treatments in 2003 were billed to the SVK that generated costs of approximately 
173 million CHF19. It is estimated that the direct medial cost of dialyses is more than 200 million 
CHF/year which constitutes about 1% of the total cost of the obligatory health insurance. In other 
words, 0, 4 ‰ of the population (2938 patients) consume 1% of the resources, each patient costing 
on average 80.000 CHF/year20. These figures do not include the cost for the treatment of 
associated pathologies and some of the medication needed for the dialysis. This renders the dialysis 
treatment one of the most expensive individual treatments within the health care system. 
In view of the above, it becomes evident that solid medical knowledge of quality criteria in 
dialysis treatment, the demand for treatment, the costs incurred and the good theoretical base for 
implementation within the existing health care system all indicate that priority should be given to 
the development of applicable national quality criteria.  
The objective of the following study is therefore firstly to propose a very simple system of 
quality evaluation of haemodialysis based on widely accepted medical quality criteria, secondly, to 
demonstrate its implementation possibility via an assessment of retrospective clinical data and 
finally to give an outlook on its medical and economic implications as well as on the 
implementation procedure. The aim is to propose an applicable evaluation tool in order to enhance 
quality management in haemodialysis treatment.  
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3. PROCEDURE AND METHODOLOGY 
In the first part of this study, key terms and key data are described followed by the definition of 
clinical, easily available and measurable parameters that give a accurate picture of the quality of 
dialysis treatment. These parameters are Urea Reduction Ratio (URR), Kt/V for dialysis efficacy; 
the amount of haemoglobin (Hb) and erythropoietin-dose for the control of anaemia; albumin, 
protein catabolic rate (nPCR) and body mass index for control of malnutrition; calcium phosphorus 
product and parathyroid hormones for control of calcium phosphorus balance as well as pre- and 
postdialytic blood pressure for the control of hyper- and hypotension. Other, not measured 
parameters will also be discussed. 
The parameters have been obtained from a literature search and in a discussion with a 
nephrologist. An excel document “Monthly reporting sheet of haemodialysis patients” was 
prepared and sent with an accompanying letter to the Directors of four private clinics in 
Switzerland, including a description of the purpose of the study (annex 1-3). The clinics were 
chosen for the reason of their affiliation to the same clinic chain that showed an interest in quality 
measures. One clinic that did not answer was called up by phone.  
Mean, median and standard deviation were calculated for the data obtained from the two 
participating dialysis centres. Standard statistical tests such as tests for comparison of means (e.g. t-
test or ANOVA) were not performed due to the rather small sample size (n = 17 patients in both 
centres). The assessment and the interpretation of the clinical data is therefore of qualitative and 
indicative nature and is mainly used to demonstrate the feasibility of the reporting. The theoretical 
system of benchmarking and its implementation scheme is discussed. An interview was conducted 
with Ms. Chevrou-Séverac relating to methodological and statistical methods, and with Dr Yves 
Eggli for the question concerning “quality”, both from the Institute of Health Economics and 
Management of the University of Lausanne (IEMS).   
 The literature search was carried out by the Centre de la santé publique of the University clinics 
of Lausanne (CHUV) on the 16/11/2005 and on the 24/11/2005 in collaboration with the author 
for the determination of the key words in English and French. The search path and the consulted 
databases are listed in annex 6. In order to complete the literature search and to have updated and 
non published data on the Swiss situation, a questionnaire with 18 to 20 open questions was 
prepared (annex 4). The questionnaire that had been slightly adapted according to the addressed 
institutions was then sent with an accompanying letter (annex 5) and the description of the study 
(annex 2) to key institutions involved in medical quality in general and to those involved with 
medical quality in dialysis treatment. The institutions were the Swiss Federal Office of Public 
Health (BAG), the Swiss Medical Association (FMH), the Swiss Society of Nephrology (SGN), its 
President and its chairman of the dialysis commission, the Swiss Federation for common tasks of 
the health insurances (SVK), the Swiss association of kidney patients (VNPS) and the 
pharmaceutical company Baxter on recommendation of the Director of the SVK. The answering 
deadline was four weeks. In the case of non replies, e-mail and phone reminders were sent and the 
deadline extended to six weeks. The answers to the questionnaire are included in the chapters 
“results” and “discussion”. 
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4. RESULTS 
4.1 DEFINITION AND DISCUSSION OF KEY TERMS AND INDICATORS 
4.1.1 Quality and Benchmarking 
Most quality improvement systems base their quality definition on the concept of the triad 
structure-process-outcomes entities, an approach introduced by Donabedian in the 1980’s and 
widely used in hospital care management.21 This approach is also used by the two dialysis quality 
systems that will be discussed within this study. Eggli and Halfon proposed a different concept that 
is independent of “outcome” and replaced by the concept of “effect”, with customers, people, 
society and key performance results being different aspects of “effects”.22 The advantage of this 
model is that the patient is considered differently, being placed in the centre of medical care and 
being attributed a more active role. This seems to be particularly important in dialysis treatment as 
the patient undergoes three times a week a life-long and demanding treatment with discomfort or 
even severe side-effects clearly attributable to the quality of the dialysis treatment. Therefore patient 
satisfaction, patient comfort and patients’ participation in the treatment process is of high 
importance in dialysis management. The purpose of this study however is to evaluate the quality of 
the dialysis on clinical criteria that are directly linked to patient well-being. In this context it has to 
be pointed out that patient or risk adjustment is important in order to prevent distortion of results, 
in particular if small sample size groups are compared.  
The OECD23 has developed selection criteria for quality indicators for macro systems such as 
health care systems but also for several pathologies and they define three dimensions for the 
importance of an indicator, for example quality of diabetes care;  
• Its impact on health. What is the impact on health associated with this problem? Does the 
measure address areas in which there is a clear gap between the actual and potential benefits? 
• Policy importance. Are policymakers and consumers concerned about this area? 
• Susceptibility to being influenced by the health care system. Can the health care system 
meaningfully address this aspect or problem? Does the health care system have an impact on 
the indicator independent of confounders like patient risk? Will changes in the indicator give 
information about the likely success or failure of policy changes?  
To break this down quality indicators should be relevant, understandable, measurable, 
behaviour- oriented and achievable. OECD also defines the standard of care as a case- and time-
specific analytical process in medical decision-making that produces a clinical benchmark of 
acceptable medical care, this benchmark used to evaluate and guide the practice of medicine.  
They introduce here the term of benchmarking24, a concept originally stemming from industry 
practices and first described by Robert C. Camp. It can be defined as a method searching for 
solutions that are based upon the best methods and procedures of the industry practice, the so-
called best practices. Two basic ideas of this concept have to be mentioned here: first the aim of 
increasing the competitiveness of the enterprise and second, the comparison with other enterprises, 
industries, thus looking beyond its own environment. Procedures, processes and methods are 
questioned in comparison with a reference point, the benchmark; usually compared to the so-called 
“best in class”. Industries compare their practices very often on an international level, even on a 
global level. The utility of the Benchmaking is the profound analysis, the identification of strengths 
and weaknesses and the elaboration of practice alternatives and solutions to problems. Conditions 
for success are that the benchmarking process is supported by the management; that the 
benchmarking team has a clear task description; that enough time and resources are devoted; and 
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that changes are accepted and implemented. Leaving the industry and looking at the reality in the 
Swiss health system, the utilization of benchmarking in the classical sense is rather rare for the 
simple reason that the main aim “increased competitiveness” is not a major objective in a non 
competitive environment.  
In the medical field Sackett et al.25 can be considered as the founders of the evidence based 
medicine concept (EBM), a concept that proposes to use some of the benchmarking tools in order 
to define best practices, with the aim to provide best quality possible across different health systems 
and different practices. The guidelines subsequently developed in various medical disciplines often 
represent a kind of step plan or decision tree to follow that defines medical practice. The success of 
its implementation however is rather doubtful as the medical practice continues to vary not only 
across countries but also within countries and regions26,27. 
Better quality will not automatically be achieved through better measuring or better control but 
it is the first step to change clinical practice in order to obtain better quality results. The 
management of the quality lies then with the responsible institution or medical officer. The variety 
of management tools is large and can even lead to the application of accounting procedures.28  
4.1.2 Medical terms and indicators29 
Function of the kidney30 - One quarter of the total blood output from the heart gets to the 
kidneys through the renal arteries. Two renal arteries arise from the abdominal section of the aorta; 
each artery supplies a lobe of the kidney. The incoming artery divides into four or five branches, 
eventually forming arterioles, each of which leads to the compact ball of capillaries called the 
glomerulus. Cell waste is discharged in the veins for excretion through the kidneys. The body 
circulates about 1000 litres of blood through the kidneys on a daily basis, but only about a 
thousandth of this is converted in urine. The remainder goes back into circulation through the renal 
veins. From the Bowman's capsule, the blood is carried through the compact network of capillaries 
that forms the glomerulus within the capsule. The capillaries eventually reconverge into small 
venules which lead to the larger renal veins. There are two renal veins, one extending from each 
lobe of the kidney, and opening into the vena cava. The nephron is the functional unit of the 
kidney, responsible for the actual purification and filtration of the blood. About one million 
nephrons are in the cortex of each kidney, and each one consists of a renal corpuscle and a renal 
tubule which carry out the functions of the nephron. In summary the main functions are regulation 
of salt, water and acid-base balance, excretion of nitrogenous and metabolic products, endocrine-
metabolic with production of hormones (e.g. Erythropoetin and vitamin D3), blood pressure 
regulation and regulation of calcium phosphorus metabolism via the parathyroid hormone.   
End stage renal disease (ESRD) is loss of renal function due to a chronic, irreversible loss of 
renal cells that requires treatment with any form of chronic dialysis or transplantation. Dialysis is 
inevitable in kidney failure that is attained at a glomerular filtration rate (GFR) of <10 - 15 
ml/min/1.73m2 body surface area. 
There are different modalities of renal replacement therapy such as dialysis (haemodialysis 
and peritoneal dialysis) and transplantation. Renal transplantations have become a widespread 
surgical procedure but the demand in human kidneys exceeds by far the offer with Switzerland 
having one of lowest rates of kidney transplantations in Europe. This underlines even more the 
importance of dialysis treatment as demand rises. Peritoneal dialysis and home haemodialysis play a 
minor role in renal replacement therapy as the “classical” in-centre haemodialysis (HD) that 
accounts for most of the treatment modalities worldwide. In Switzerland 89 % of all dialysis 
patients were treated with HD in 200531 that accounted for nearly 92 % of the direct costs of renal 
replacement therapy in 2003.32 For this reason we will only discuss the in-centre haemodialysis 
treatment.   
The principle of haemodialysis is to remove nitrogenous (and other) waste products, and to 
correct the electrolyte, water, and acid-base abnormalities associated with renal failure. Dialysis does 
not correct the endocrine abnormalities of renal failure, nor prevent cardiovascular complications. 
It requires the use of a semi-permeable membrane that will allow the passage of water and small 
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molecular weight such as urea and creatinine. Dialysis, in fact refers to the diffusion of solutes 
across a semi-permeable membrane down a concentration gradient. At its simplest, a dialysis 
machine simply pumps blood and dialysate through a dialyser, the dialysate being a solution of 
water, sodium, potassium, magnesium, calcium, chloride, dextrose and bicarbonate. The blood and 
dialysate are kept separate within the dialyser by a semi-permeable membrane. As the dialysate 
contains no waste, products of metabolism (urea, creatinine, etc.) these will diffuse from blood into 
dialysate. 
Most of the guidelines (K/DOQI and European best practice guidelines) and the quality in 
nephrology QiN-system propose to measure indicators that reflect seven main problem areas in 
dialysis. These are dialysis adequacy, hypertension/cardio-vascular system, renal anaemia, calcium-
phosphate metabolism, malnutrition, vascular access and inflammation33. In the following all the 
criteria chosen for the assessment in the haemodialysis reporting sheet (see annex 3) are discussed. 
Dialysis adequacy – an adequate dialysis maximizes well-being, minimizes morbidity, and 
helps a patient retain social independence. An optimum dialysis is a method of delivering dialysis 
producing results that cannot be further improved. There are several factors influencing the dialysis 
adequacy but in the criteria it is focused on the Kt/V that reflects the adequacy of the delivered 
dose of haemodialysis and its relation to effects on the patient34. The amount of dialysis delivered 
during a single treatment is measured by the computed terms Kt/V or Urea Reduction Ratio 
(URR). Kt/V means the clearance of the dialyzer multiplied by the time of dialysis, with this value 
divided by the patient's urea volume (38%-63% of the patient's weight, essentially the total body 
water). Kt/V is calculated in a manner similar to Urea Reduction Rate (URR). URR is usually 
expressed as a percentage, sometimes as a ratio (R). It is calculated from the pre- and post blood 
urea nitrogen. The two methods of measurement are mathematically equivalent when all factors are 
considered. The mortality seems to decline the higher the Kt/V35, the European practice guidelines 
recommending a Kt/V ≥1.4 and the UK Renal association a URR of ≥ 65%. 
Hypertension/cardiovascular system – the cardiovascular risk in dialysis patients is 
considerably increased with a nearly nine fold higher probability to die of a cardiovascular disease 
compared to the general population36 and cardiovascular causes being the most common reason for 
death in dialysis patients37. Cardiovascular management is included in some of the indicators already 
presented but the blood pressure should be measured to control hypertension as one of the most 
important risk factors for cardiovascular mortality. The recommended target value is a blood 
pressure (BP) of ≤ 130/80 mmHg according to the K/DOQI guidelines. In this study pre-and 
postdialytic BP were measured the predialytic BP for the evaluation of hypertension and the 
postdialytic BP for the monitoring of eventual hypotension, a common phenomena after dialysis 
and an indicator for patient well-being immediately after dialysis.  
Renal anaemia is primarily due to a lack of erythropoietin (EPO). Other causes are uraemic 
and cytokine inhibition of the erythropoesis, deficiencies of iron, folic acid and vitamin B12, as well 
as hyperparathyroidism and haemolysis. Most importantly erythropoietin and iron have to be 
replaced in order to obtain sufficient haemoglobin (Hb) levels that are 11-14 g/dl according to 
EBFG38. Each decline of 1g/dl Hb below 11g/dl Hb increases the mortality risk by 13 %39 and the 
partial correction of anaemia by maintaining haemoglobin in the range of 11-12 g/dl is associated 
with a 10% to 74% decrease in the risk of death and a 7% to 58% decrease in hospitalization 
compared with lower Hb levels40. Haemoglobin is also a key parameter as performance, living 
quality41 and cognitive functions improve with higher Hb levels and as cardio vascular symptoms, 
ventricular hypertrophy and hospitalization rate42 and frequency decrease if the target values are 
achieved43. The dose of erythropoietin is monitored in order to diagnose an EPO resistance that 
would then need further investigation.  
Calcium-phosphate metabolism – hyperphospataemia is a predictable consequence of 
chronic renal failure and is present in most patients on dialysis, contributes to renal osteodystrophy 
but more importantly increases the risk of cardiovascular death in this population as abnormalities 
in calcium phosphorus product (CaxPO4) and parathyroid hormone (PTH) levels result in vascular 
and visceral calcification44. Odds ratio for mortality increased in a nationwide study by 1.34 for 
CaxPO4 levels between 5.89 and 10.65 mmol2/l2 45. In a more recent study, patients exceeding the 
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target values had a 27% higher mortality than patients within the target range46 and a Dutch study 
found that all-cause mortality risk increased in haemodialysis patients by 40% if CaxPO4 was greater 
than the K/DOQI targets47. The recommended target values are ≤ 4.44 mmol2/l2 for CaxPO4 and 
16.5-33 pmol/l for PTH48. 
Malnutrition is a common phenomenon as patients spontaneously reduce their protein intake 
as well as their overall calorie intake with some becoming severely cachectic. For evaluation of 
malnutrition Body Mass Index (BMI), albumin and protein catabolic rate (nPCR) are used the latter 
defining the protein intake49. These parameters are easy to measure and to calculate and give a good 
picture of a nutrition status, the BMI being the parameter for the general nutrition status and 
closely associated with survival in haemodialysis patients50. It seems that the higher the BMI and the 
percentage of muscle mass51, the better the survival rate. Severely and moderately malnourished 
patients had a higher mortality risk compared with those well nourished: 33% and 5 % higher, 
respectively52. Albumin is a parameter for the general nutrition and a reliable predictor of mortality 
for patients undergoing haemodialysis53. Target value for albumin is ≥40 g/l and for nPCR = 1.2 
g/kg body weight/day54. 
Vascular access patency is crucial for patients with ERSD as haemodialysis access failure has 
become the most frequent cause for hospitalization among ERSD patients55. The problems caused 
are mostly due to the lack of patency which requires intense treatment such as surgical 
interventions or catheter interventions. A shunt infection is a rare but severe complication. Patency 
and infection rate with a variety of causes should be monitored for each patient on a yearly basis. 
This is the reason why this criterion has not been included in the reporting sheet.  
Inflammation56 - CRP predicts outcomes and improves inflammatory risk prediction. 
Therefore, it would be beneficial to assess CRP levels in dialysis patients on a regular basis, and to 
seek sources of infection or inflammation. A highly sensitive method for measuring CRP is 
recommended but has not been measured due to local clinical practice and due to non-
reimbursement by the health insurer. Various causes of inflammation may be identified in dialysis 
patients. Overt and occult infectious processes require appropriate treatment. Factors associated 
with dialysis treatments that may provoke an inflammatory response include impure dialysate (due 
to endotoxin or bacterial contamination), back-filtration, and bio incompatible dialysis membranes.  
In conclusion the quality indicators chosen measure the effects of the dialysis on the patient via 
clinical parameters or laboratory values. These parameters are evaluated routinely in clinical settings 
either on a monthly (Hb, CaxPO4) or a quarterly basis (PTH, Kt/V, URR, nPCR). Albumin is 
measured every six months.  All other parameters can be evaluated by calculations or simple non-
laboratory procedures such as BP measuring.  
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4.2 DATA OF THE REPORTING SHEETS AND OF THE QUESTIONNAIRE 
Two out of the four clinics responded and sent the monthly reporting sheet for the month of 
November 2005, for the individual clinical patient data (see annex 7). The two dialysis centres had 
each gathered data on 17 patients. The sheet was judged self-explanatory by the participating 
medical doctors, therefore no assistance was required. Mean; median and standard deviation (StD) 
are presented in table 1. As mentioned in the chapter procedure and methodology, a statistical 
analysis was not performed despite the fact that the goal of the benchmarking is to compare 
different data sets. The presented data does not show whether the difference in mean and median 
can be attributed to variance in medical care or to the variance in the patient groups. Therefore, 
routine statistical tests such as t-test (also called student test) for comparing the means of two 
groups or the ANOVA, which compares equality of means in several groups were not performed 
as some of the prerequisites of the model such as equal standard deviations between groups could 
not be assured. Other, more elaborated statistical procedures would need to be applied here such as 
non-parametric tests but this would go beyond the scope of the present study.  
However, in the case of the implementation of a quality system this issue would deserve 
particular attention in the methodology, as a risk adjustment for different patient groups would be 
necessary, and as quite a few of the 79 dialysis centres in Switzerland are small in numbers of 
treated patients. Looking at the data it can be stated that gender, age, attendance and BMI are 
similar in both clinics. The variance of PTH in clinic 2 is striking and the difference in kt/V single 
pool is noticeable. Clinic 1 exceeds here with a mean of 1.74 the values recommended by most 
guidelines and clinic 2 reaches the target value. Apart from these differences it can be said that 
taking into consideration all methodological constraints the quality outcomes are not very different 
given a similar population in terms of gender and age, in particular as most of the target values of 
the chosen guidelines are met. The exception is the blood pressure which is in both clinics higher 
than recommended in the guidelines and seems to be higher in clinic 2 than in clinic 1. The EPO 
doses differ in the two clinics but are not interpretable due to the wide individual variation. The 
costs for the treatment with EPO are approximately 48 CHF higher per patient/week in clinic 1 
than in clinic 2 based on an average price of 23.54 CHF/1000 units EPO with significant variations 
pending on the volume.   
Four hours were needed by both clinics to gather the data and to complete the sheet for 17 
patients. Clinic 1 evaluates the proposed quality criteria regularly; the other did not evaluate nPCR, 
EPO/kg and BMI in their regular scheme. This implies that in both clinics no additional laboratory 
were generated and in clinic 2 nPCR, BMI and EPO/kg can be simply calculated. The overall 
estimate for the implementation costs for completing the form can be estimated at most, at four 
hours working time of the physician or a trained nurse and sums up to approximately 160-200 
CHF/evaluation for the nurse and 420 CHF/evaluation for the nephrologist based on average 
Tarmed position 00.0140 (physician service in absence of the patient)57, thus meaning that a quality 
evaluation with the proposed system costs on average between 10 - 25 CHF/patient evaluation and 
approximately 40 - 100 CHF/patient/year. One clinic expressed its regret not to participate for the 
reason of a new incoming head of nephrology and in the other clinic, the responsible nephrologist 
confirmed firmly by phone the “danger” of such a study that lies in comparing different dialysis 
centres.  
As mentioned in chapter 3 the questionnaire in annex 3 has been sent to eight different 
institutions representing the different parties involved in medical care. Surprisingly, the Swiss 
Society of Nephrology (SGN) and the President of the dialysis commission, concerned primarily 
with the issue, did not answer, neither to several e-mails nor to letters. The FMH referred to the 
SGN for further questions and the BAG did not see itself in the position to answer for the lack of 
human resources. The patient organization (VNPS) responded that their medical collaborator 
would take care of the response. Finally the only questionnaire received in time came from the 
health insurers who confirmed their interest in participation and in the results of the study. Baxter 
and VNPS responded after the deadline so that the answers could only partly be taken into account.  
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TABLE 1: OVERVIEW OF CLINICAL DATA (N=34), SEE ANNEX 3 FOR EXPLANATIONS OF THE 
CRITERIA, THE CRITERIA IN BOLD ARE MAIN CRITERIA FOR DIALYSIS QUALITY. THE TARGET 
VALUES ARE DEFINED IN CHAPTER 4.1.2. 
CRITERIA 
 
MEAN 
CLINIC 1 
MEAN 
CLINIC 2 
MEDIAN 
CLINIC 1 
MEDIAN 
CLINIC 2 
STD 
CLINIC 1 
STD 
CLINIC 2 
TARGET  
VALUE 
GENDER RATIO  
MALE/FEMALE 
1.8 
 
1.8 
 
- 
 
- 
 
- 
 
- 
 
- 
 
AGE RANGE 4.2 4.9 4.0 5.0 0.9 1.0 - 
ATTENDANCE IN % 100 100 100 100 0 0 - 
HB (G/DL) 11.8 12.6 11.9 12.4 0.8 1.1 ≥ 11 
BMI (KG/M2) 24.6 22.1 24.0 22.0 5.4 2.9 - 
CA X PO4 MMOL2/L2 3.58 4.33 3.68 4.42 0.84 1.01 ≤ 4.44 
KT/V SINGLE POOL 1.74 1.43 1.75 1.41 0.33 0.29 ≥ 1.4 
EPO DOSE (UNITS) 8676 6533 6000 6000 6065 2850 - 
EPO/KG BODYWEIGHT 129.8 109.3 86.9 115.0 98.8 48.1 - 
PTH (PMOL/L) 14.0 30.6 12.7 14.1 8.8 42.7 16.5-33 
URR (%) 77.0 70.1 79.0 70.5 6.1 7.1 ≥ 65% 
NPCR (G/KG/DAY) 1.04 1.17 1.07 1.19 0.14 0.29 1.2 
ALBUMIN (G/L) 37.0 37.1 38.0 38.0 4.7 3.4 ≥ 40 
PREDIALYSIS SYST. BP 
(MMHG) 
151 
 
161 
 
157 
 
164 
 
22 
 
36 
 
130 
 
PREDIALYSIS DIAST. 
BP (MMHG) 
78 
 
81 
 
80 
 
79 
 
10 
 
16 
 
80 
 
POSTDIALYSIS SYST. 
BP (MMHG 
135 
 
149 
 
130 
 
148 
 
23 
 
31 
 
- 
 
POSTDIALYSIS DIAST. 
BP (MMHG) 
72 
 
78 
 
71 
 
80 
 
12 
 
14 
 
- 
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5. DISCUSSION  
One of the basic questions that could be asked is why is it necessary to measure quality if there is 
good and similar quality prevailing in Swiss dialysis centres? A very simple answer is that nobody 
knows that the quality is good and similar across Swiss dialysis centres as systematic evaluations 
have not yet been published or carried out. In the minutes of a meeting of the dialysis commission 
of the SGN in September 2002 it can be read that a registry shall be established and that this 
registry shall incorporate quality control and quality assurance measures58. However, the literature 
search, the search of the website of the SGN and the answers to the questionnaires has not 
produced any answers. Significant differences in quality are common across countries. Patients on 
dialysis have a 30 % higher mortality in the US than in Europe and the mortality rates differ within 
European countries too59 and these cannot solely be reduced to patient mix. The German60 and the 
American61 experience show that there are significant differences in medical quality between dialysis 
facilities and within regions. Furthermore quality programmes lower mortality (up to 31%), 
decrease costs62 and improve quality of life63. Therefore it is in everybody’s’ interest to have data 
about mortality and living quality of dialysis patients in Switzerland, that, according to the findings 
of this study are non-existent. The conclusion is that quality differences are to be expected within 
Switzerland and between different dialysis treatment facilities and that it is necessary to measure 
quality in order improve quality, and consequently mortality and living quality. In the following the 
need for the proposed quality evaluation from different perspectives and an implementation 
proposal will be critically discussed. 
5.1 MEDICAL CONSIDERATIONS 
As described in chapter 4.1.2 several evidence based guidelines on dialysis treatment exist defining 
different target values according to findings in randomized controlled clinical trials. They constitute 
the base for a sufficient relationship between clinical parameters and mortality as well as living 
quality. The two main initiatives launched in the closing years of the past century with the goal of 
improving the treatment outcomes of patients with kidney failure were the Kidney Disease 
Outcomes Quality Initiative, which formed expert panels to develop evidence-based clinical 
practice guidelines, and the Dialysis Outcomes and Practice Patterns Study (DOPPS), which 
gathers data on practice patterns in dialysis facilities in 12 countries, including the United States. 
Three years ago, the Kidney Disease Improving Global Outcomes (KDIGO) program was 
established to promote worldwide coordination and integration of initiatives to develop and 
implement clinical practice guidelines and to provide new opportunities of cooperation with the 
international scope of DOPPS. Collaboration between the DOPPS and KDIGO should lead to 
broader dissemination of relevant information to nephrologists, health care providers, and patients. 
Linking the DOPPS scope of work with the KDIGO goals should help develop continuous quality 
improvement programs and the provision of direct feedback to participating dialysis centres 
throughout the world. This should establish an essential component in the translation to clinical 
practice of evidence-based guidelines worldwide64.  
However, the reality seems to be different as education and treatment guidelines alone are not 
likely to be effective: there are numerous barriers to physician adherence to treatment guidelines, 
such as lack of awareness, lack of agreement, and the inertia of previous practice65. Guidelines for 
dialysis treatment are, in general, accepted among the medical community but the adherence to 
guidelines still seems questionable as the conclusions of several articles dealing with dialysis topics 
expressed: “The magnitude of potential savings in life years should encourage greater adherence to 
guidelines and practices that are significantly associated with better survival”66; “while there is 
evidence that the guidelines are slowly being adopted, there remains much room for improvement 
in their implementation”67; or “although some improvements can be documented in anaemia 
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management practices in the years after the publication of international guidelines, wide variations 
in anaemia management are still observed among countries”68. Another reason for non-adherence 
to guidelines may be the definition of target values that are practically difficult to achieve even after 
adjustment of case mix. Several studies report either the low percentage of patients achieving one 
or several target values or they criticise the validity of the target as such. In a study on the bone and 
mineral metabolism, PTH levels were within the values recommended by K/DOQI guidelines in 
only 20% of the determinations and only 7% of the determinations met all four criteria of bone and 
mineral metabolism simultaneously. They conclude that current practice for the management of 
bone and mineral metabolism in haemodialysis falls far short of meeting K/DOQI guidelines69. 
Another study found that the mean haemoglobin in erythropoietin-treated haemodialysis patients 
varied substantially and was between 10.9 and 11.2 g/dl. They also conclude that the K/DOQI 
recommended haemoglobin range appears to be too narrow in clinical practice70. Kt/V, the key 
indicator for dialysis adequacy is at the forefront of these discussions. The higher the Kt/V the 
better the survival time as proven in several studies71, (see also above), but there is evidence that a 
higher dialysis dose than Kt/V > 1.2 will not improve survival but that it is much more important 
to reducing to zero the number of times the dialysis dose is delivered at a Kt/V < 1.272. An Italian 
study adds that they found the optimal cost-effectiveness for the dialysis dose at a Kt/V of 1.373 
thus questioning the recommendation of the European practice guidelines of a Kt/V > 1.4 that has 
been chosen as the target value in this study.  
Putting oneself into the position of a physician in charge of a dialysis unit it may be 
understandable that adherence to guidelines may be complicated if most of the targets are difficult 
to meet and not knowing whether these targets reflect in fact best clinical practice as the example of 
discussion of the indicator Kt/V shows. The variations will not increase adherence in particular if a 
set of guidelines is not clearly recommended by the local or the national professional body as in the 
case of Switzerland. Furthermore observational studies only reveal associations and are limited by 
selection bias and confounding. The Kidney Disease Outcomes Quality Initiative guidelines 
(K/DOQI) as well as all other guidelines on dialysis adequacy are based on results of observational 
studies and expert opinion74. Another possible bias that may be considered in the drafting of 
guidelines is the financial contribution of the pharmaceutical industry to organisations that are in 
charge of the guidelines, e.g. the National Kidney Foundation (NKF). Unfortunately the annual 
report of the NKF did not clearly indicate the financial support received from the industry75. 
However Amgen, an important Erythropoietin producer is a “Platinum sponsor” of the National 
Kidney Foundation (NKF) responsible for the K/DOQI guidelines76 and EPO products increase 
the haemoglobin levels. Thus it could be of economic advantage for Amgen that higher 
haemoglobin values are recommended in guidelines. Despite these raised questions about the 
confidence in guidelines it is believed that the medical evidence is strong enough to propose the 
reporting sheet used in this study as the potential benefits outweigh methodological constraints.  
As said in the introduction the purpose of this study is not to evaluate different dialysis centres 
but to demonstrate the application of a system that is practical and that can be easily included in 
daily practice. This has been confirmed by the participating nephrologists who confirmed the self 
explanatory nature of the formula. Added criteria for example the evaluation of the vascular access; 
inflammation; and of living quality of the patient should be added and shall form an integral part of 
any quality assessment. In order to keep the implementation costs as low as possible and in order to 
reduce the implementation resistance to a minimum and in order to keep the system as simple as 
possible it is proposed to reduce even further the chosen criteria to five; namely to Kt/V for 
dialysis adequacy, blood pressure for hypertension, Haemoglobin for renal anaemia, CaxPO4 for 
calcium-phosphate metabolism and body mass index for malnutrition. An evaluation of these 
indicators shall be monitored quarterly and BP is measured routinely before each dialysis. These 
indicators will sufficiently cover all main areas for dialysis quality. Target values will not be 
mentioned in the reporting sheet as the responsible medical bodies have not yet recommended a 
guideline nor target values to be achieved.  
If there is no variability in the data the necessity of a further quality control could be questioned. 
However the likelihood of finding variability of the data is very high. It is then important to identify 
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whether the variations are related to dissimilarity in the process of care or due to the case mix77, in 
particular as the dialysis centres are small in patient numbers and normal distribution of patients 
cannot be taken for granted. In the example of the two clinics it can be seen that the mean in the 
PTH levels in clinic 2 is more than twice the level in clinic 1 which is most probably due to one or 
two patients having an excretional dysfunction explaining these high levels of PTH. These outliers 
would need to be identified for the comparison of the two populations.  
Even if the comparison between the two dialysis centres is statistically difficult and only of 
indicative and qualitative nature certain differences can be clinically observed that may partly be 
influenced by different medical practice. First of all it must be said that nearly all target values are 
achieved which is rather uncommon looking at other findings in literature. Apparently there is a 
selection bias as the two clinics voluntarily participated in the study and it can be presumed that 
they have an interest in the quality issue and provide therefore good care. However the 
hypertension management is in both clinics not optimal and in clinic 2 slightly worse than in clinic 
1. This may be explained by either the guidelines not matching the reality as a nearly normal blood 
pressure is the target value which is difficult to reach in a population of older age or in a population 
with several comorbidities. Another explanation may be indeed medical practice; here the 
antihypertensive therapy may not be following the recommendations of evidence based medicine. 
In this context a clinical centre in Germany has clearly demonstrated how the antihypertensive 
medication has been reduced due to better quality control in dialysis treatment78. 
What criteria are used by others in evaluating quality in haemodialysis treatment? Here the 
biggest insurer of dialysis treatment worldwide, Medicare uses three criteria for three areas of 
dialysis quality, namely haematocrit for renal anaemia; Urea Reduction Ratio (URR) for dialysis 
adequacy; and patient survival for the outcome. The first two criteria allow only a limited 
assessment of the quality of dialysis as explained in 4.1.2. Therefore haematocrit should be replaced 
by haemoglobin and the URR by Kt/V being more reliable indicators. Medicare benchmarks the 
facilities in comparison with other facilities in the region and in the US as a whole. The results and 
the dialysis facilities characteristics are made publicly available on the net at www.medicare.gov. The 
Quality in Nephrology (QiN) programme79 uses a very extensive set of indicators covering all main 
areas of dialysis quality, living quality of the patient as well as morbidity via hospitalization rate and 
mortality. The results are available for the participating facilities but can only be compared on a 
single blind basis. After five years of implementation the results are very positive with a better living 
quality and a significantly better dialysis quality in nearly all parameters. The targets for Hb, Kt/V, 
CaxPO4, and BMI are met and reach similar values than the two participating clinics in this study. 
The only difference lies in the Blood Pressure levels, QiN nearly meeting the targets with levels 
lower than the two clinics in Switzerland. The most important finding is that the quality improved 
in the participating centres without any economic or other linkage but simply caused by the fact of 
comparing different facilities between each other. This may be attributed to the awareness effect 
and the better consideration of guidelines in the daily medical practice.  
Another important factor, particularly in view of the small dialysis centres in Switzerland is the 
risk adjustment in order to avoid patient selection bias.  In the US example80 the case mix measures 
are age and two body measurement variables, body surface area and body mass index whereas the 
German experience81 uses age, albumin, diabetes mellitus, eventually gender and others according 
to the analyses. This study proposes a case-mix adjustment for age, diabetes mellitus and 
hospitalization which is an indirect indicator for severe comorbidities. Looking at these experiences 
abroad, the following indicators should be included in the evaluation but do not need to be 
included in the regular reporting sheet; vascular access problems; and hospitalization rate and 
duration that can be retrospectively evaluated for each patient via the patient history file. The living 
quality and the patient participation will be discussed in chapter 5.3.  
In conclusion, several quality programs exist and they vary extensively. Benefits for the patient 
can be expected via quality control measures and the medical evidence seems to be sufficient to 
justify the proposed reporting sheet. The return of only one questionnaire raises concerns about the 
interest in a transparent quality control system of the different actors and in particular the medical 
community.  
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5.2 ECONOMIC CONSIDERATIONS 
The basic question to ask here is whether it makes sense to evaluate quality and to foster quality 
management from an economical perspective. Renal replacement therapy for end-stage renal 
replacement disease has arguably been among the first medical technologies to be assessed with 
regard to its costs and outcome. This is certainly related to the large and vastly expanding number 
of potential beneficiaries of such treatments, in combination with large per patient treatment costs. 
Since then hardly any other medical technology has been assessed so regularly in so many countries. 
One reason for this “popularity” seems to be the decision of the US government to entitle patients 
with ERSD to reimbursement of the costs of renal replacement therapy within the Medicare 
programme in 1972. This was the first and thus far the only time that health coverage was granted 
in the US solely on the basis of a diagnosis. This may have had an effect on the European and the 
Swiss reality as access to renal replacement therapy (RRT) is in principle guaranteed; thus the 
provider structure influencing access and choice of treatment. The UK however has age restrictions 
on access to RRT82. This guaranteed access to RRT in Switzerland may change in the future if 
revenues tend to fall and health expenditure keeps growing as demand rises. As the achievement of 
the impossible is impossible the relationship between the resources spent and the health outcomes 
or health effects obtained will be increasingly and controversially discussed83. In this regard policy 
makers will increasingly want to know what they pay for and then it will be important to prove the 
necessity and the quality of the intervention, here haemodialysis treatment. Unfortunately and due 
to the lack of studies on the relationship between dialysis treatment, financial burden and quality in 
Switzerland the following discussion has been constructed with the assistance of foreign data and 
must not be mistaken with a full-fledged economic evaluation.  
First of all the potential demand for this type of treatment in the future will be looked at. The 
prevalence of kidney failure in the US population is approximately 0.2%. Added to this, 0.2 % of 
the US population is living with severe kidney damage with a GFR of 15-29 likely to develop at 
some stage ESRD. Mean incidence of ESRD across Europe between 1990 and 2000 rose from 79 
to 117 new patients per million population per year (PMP). The unadjusted prevalence of dialysis in 
France was 513.1 patients per PMP in 2003, one of the highest in the world84. The prevalence in 
Switzerland in 2000 was 332 PMP and the incidence 145 PMP with a sharp increase over the last 
years.85 Interesting in this respect is a study of 1973 that counted 376 patients on dialysis in 
Switzerland compared to more than 3000 today and that estimated some 135 PMP with ERSD for 
the beginning of the 80’s86.  
A survey indicates that the annual average global increase of ERSD is about 6% with Europe 
being at lower increase rates87. The two main reasons are higher incidence of diabetes type 2 in the 
western society and the ageing of the population, diabetes and Glomerulonephritis accounting for 
40% of the causes for ESRD in Europe whereas in the US diabetes is the leading cause with 44% 
of all patients starting dialysis being diabetic. In the UK prevalence increased hugely with age from 
78 PMP in those < 40 years and to 58913 PMP in those ≥ 80 years.  
Subsequently this has lead to a higher demand and will lead to an even further increase in renal 
replacement therapy as the European and Swiss population are ageing. The trend of the US with 
where the proportion of diabetic patients starting dialysis doubled over the last 20 years is making 
its way to Europe and can be partly attributed to the alarming increase in obesity. Diabetes in 
Germany is already the main cause for ERSD with 36% of all causes.88   
Comorbidity is increasingly common in patients with ESRD with heart failure, diabetes and 
coronary artery disease at the top of the list. Nevertheless the death rate of dialysis patients has 
decreased over the last years which again may increase the demand for ERSD as patients will profit 
from a better survival rate.   
Looking at these incidence and prevalence data I conservatively estimated a yearly increase of 
8% for patients on dialysis in Switzerland that is a compromise between the 6% increase of ERSD 
of the study above and the 11.8% increase registered by the SVK. 8% of about 3000 patients on 
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dialysis is “only” 240 new cases each year but implying an added yearly financial burden of direct 
medical dialysis treatment costs in the range of 19.2 million CHF (240x80.000 CHF) constituting a 
10% increase each year that is well above the 5% increase in the total health costs between 2002 
and 2005 and still higher than the expected yearly increase of 3-4% up to 201089.  
Winckelmayer et al.90 conducted a meta-analysis on cost-effectiveness studies in ERSD and 
found that the only cost element in all studies included were direct (medical) costs. Hardly any 
study made an attempt to include lost earnings, patient time cost for treatment, informal caregiving 
or transportation, thus meaning that indirect costs or human costs are in general not available. They 
concluded by stating that their analysis makes it tempting to recommend the use of RRT as a 
referent for the lower boundary of societal willingness to pay for an additional life year that would 
translate into approximately $ 61000 ( ≈ 80.000 CHF) per quality adjusted life year (QALY). The 
study however includes renal transplantation as a method of RRT and reviewed only literature 
published in English. This figure adjusted for different purchasing power reflects approximately the 
direct dialysis medical costs per patient in Switzerland. In this context it would be interesting to 
know about other costs in order to get a full picture of the costs and to forecast cost development. 
These other direct medical costs are for example better and more expensive technology (new 
and more expensive versions of Erythropoietin, new generations of filter systems etc.) and 
treatment costs for associated pathologies. The estimated yearly increase that has been calculated 
(19.2 Mill. CHF) includes only the costs of the treatment as specified in the contract of the SVK 
with the service providers91. According to this contract a haemodialysis treatment is reimbursed on 
a flat-rate basis with 448-497 CHF comprising all services of the haemodialysis treatment except the 
reimbursement for EPO. The treatment costs of most of the complications as well as the treatment 
costs of other pathologies remain with the individual insurer who bears nearly all financial risks. 
Despite the fact that art.5 of this contract says that the dialysis providers commit themselves to 
participate in efforts to control and assure quality, a concise contract or memorandum of 
understanding concerning quality has not yet been established between the SVK and the provider. 
In conclusion there is hardly any economic incitation for a provider to deliver good quality of 
haemodialysis treatment and not much more for the SVK either as the costs for the treatment of 
the comorbidities (e.g. hypertension and diabetes) are with the individual health insurer of the 
patient. These findings are confirmed in several studies, admittedly in a different health care 
concept, here the US system. In 1994 already it was stated that the Medicare ERSD programme can 
hope to provide quality patient care only through a systematic linkage of cost and quality 
measurements92. This has been confirmed and emphasized six years later by putting forward a more 
effective model which is to improve quality, and which called for inclusion of external standards 
and quality assurance; internal, confidential quality improvement programs in all dialysis facilities; 
and the provision of sufficient information to the Health Care Financing Administration (HCFA) 
and state regulatory agencies on processes and outcomes of care93. Some European countries 
introduced or have begun to introduce regulatory mechanisms or economic incentives considering 
health effects or health outcome in dialysis. In Germany a legal bill is to be expected in which 
certain standards on structure and dialysis effects are to be reported. Monetary penalties are 
planned in case that the results are more than 15% below target value94 whereas in France a global 
concept has been implemented related to the accreditation process in the hospital reform of 1996 
that provides guidelines for clinical practice but also sets standards for quality indices and the 
control process95. In Switzerland though nothing of all this has been done so far and once the 
formal accreditation is granted the provider may operate without reporting any data on quality96.  
In order to justify the effort of quality evaluation and quality control an important question is 
whether good quality has an impact on several key indicators such as mortality, living quality and 
direct medical costs. As described in chapter 5.1. mortality is likely to decrease if good quality 
treatment is provided but unfortunately studies that combine the impact on mortality if several 
target values are achieved and longitudinal studies are not available. If mortality decreases, which is 
a trend observed, this also leads to higher costs for the health care system as patients remain longer 
on a very cost- intensive treatment, this however not being different from other life extending 
interventions.   
 17 
The living quality increases if the target values for several indicators are met as discussed in 
chapter 4.1.2 and 5.1. Only one study mentioned that the use of EPO increases the quality of life 
but that its use imposes a 10% rise in the cost per life year saved97. Unfortunately this article does 
not reflect the European reality. Another article treated the cost factor of technology diffusion to 
the elderly while estimating the medical cost for patients > 75 yrs. 10% higher at the example of 
bypass operations and dialysis98.  
Does a good quality dialysis have an impact on direct medical costs? Erythropoietin is a 
hormone that stimulates the production of red cells and is a mainstay in the treatment of patients 
with anaemia of chronic renal failure, decreasing transfusions and improving the quality of life of 
patients who receive it. About 12% of the average annual cost per patient on dialysis is spent on 
medication according to a British study99. This percentage may even be higher in Switzerland as the 
prices of medication and in particular EPO are significantly higher. Patients that developed 
hypertension in dialysis treatment will need about 40% more EPO than those without pre-existing 
hypertension100, thus implying if hypertension is better controlled the costs for the EPO treatment 
could decrease by 40%. Another publication found that EPO costs are 13% higher (140 
CHF/patient/month, extrapolated by the author) in case where patients are not dialyzed 
adequately101. The savings due to reduced hospitalisation rates through the use of EPO were 
mentioned several times in the chapters 4.1.2 and 5.1 but only one publication tried to evaluate the 
potential savings in monetary terms and despite certain methodological constraints the benefits may 
be considerable102. These findings emphasise the economic benefit on direct medical costs that can 
be derived from a good quality management. The potential savings will outweigh the costs of the 
quality system by far as the QiN experience indicates, even though no monetary benefits were 
calculated.  
In conclusion, the demand for a very expensive medical intervention will rise significantly and 
the costs will too. The payment to the service provider is independent of the quality effects 
produced although the medical costs may be positively influenced by good quality treatment. 
Therefore the service providers shall be firmly encouraged to participate in the quality evaluation by 
applying art.5 of the contract between service provider and insurer. Furthermore it is recommended 
to conduct a thorough economic cost-effectiveness or cost-benefit study examining at least all 
direct medical costs of patients on dialysis treatment in Switzerland.  
5.3 THE ROLE OF THE PATIENT  
As mentioned in the first sentence of the introduction,  the health systems’ basic aim is to make 
lives better for most of a given population that is experiencing some kind of illness. It seems logical 
that the consumer, client or patient, whatever term is used depending on the perspective, should be 
the focus of all action. Unfortunately there are severe barriers to this achievement as Domenighetti 
et al. state in an article of 1997103. These are the myth surrounding the effectiveness of medicine 
that seems still to be prevalent among the public and the paternalistic patient-physician relationship 
that is still predominant in the clinical environment of many countries. He proposes the 
empowerment of the patient via informing him that may lead to an aware customer putting 
pressure on the health care professional so that the latter will finally change from opinion or market 
based medicine to evidence based medicine. A systematic review104 on this subject however comes 
to the conclusion that patients have contributed to the planning and development of services 
(mainly on structure and information sources) across a range of settings but that the effects of this 
process on the quality and effectiveness of services are unknown, mentioning a possible barrier on 
the policy side, as strong patient opinions can influence health care decisions to the disadvantage of 
policy makers. A similar barrier may be expected from the medical side as a demanding and well-
informed patient may lead to a power struggle with the “expert”105.  
What is the situation in the treatment of patients on dialysis? The patient on dialysis is a 
chronically and severely ill patient who is on life-long treatment if he cannot expect a kidney 
transplant. He is dependent on the regular dialysis treatment as he would otherwise die in a short 
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time span. He spends on average 3 times a week 4 hours of intense treatment in a clinical setting 
with possible side effects ranging from hypotension, cramps, nausea, to vomiting and headache, all 
this linked to the treatment itself. He spends at least 15 hours a week a clinical setting never sure of 
how he will feel afterwards and knowing that the mortality rate is high. The living quality of this 
person is therefore substantially decreased. The setting is very stable as the patient usually does not 
change the dialysis facility and modality of treatment. This may alter the relationship of patient to  
nurse/physician compared to other diseases such as cardiovascular diseases with short term 
interventions and often higher living quality. The patient on dialysis seems to be the “ideal” patient 
for involvement in the treatment process as his mental state is not affected and that the treatment 
as such influences greatly his living quality106. This attitude is mainly shared by the medical 
profession on theoretical level or as one article states107: “customer relationship management 
assumes that the patient is seen as a client, is encouraged to make decisions on their treatment and 
also emphasises the professionalism of nursing”. Bath et al. reported that the need for good quality 
information, the need for a suitable dialysis environment and the importance of social and family 
support were evident for haemodialysis patients108.  
Several other publications report positive experiences with patient involvement of any kind; a 
Dutch study demonstrates the feasibility of the implementation of changes which were asked for by 
the patients two years ahead and confirmed this procedure as a useful tool in quality 
improvement109. A Swiss report found a significant positive correlation in similar patient groups 
between the amount of dialysis self-care and subjective well-being, thus implying that active 
participation in the care process increases living quality110.  
Two articles treated the patient-nurse/physician relationship with one even observing a 
relationship between patient satisfaction with care with their nephrologist and attendance at dialysis 
sessions, indicating that interventions aimed at improving the patient perception of physician 
support may improve patient adjustment and possibly survival111. The other publication emphasises 
that dialysis patients are willing to participate in shared-decision making112. Shared decision making 
could however become difficult if as an American study describes 75% of patients would choose a 
high dose over a lower dose of dialysis if it increased length of survival by 20%, but more than 30% 
would not switch modality, even if it increased survival by 100%. This implies that dialysis patients 
have strong preference for their current modality113.  
Despite all methodological constraints of the above mentioned publications and the rather weak 
relationship of patient involvement and its effects on health care, the patient involvement remains 
indispensable for several reasons. The patient involvement can result in better implementation of 
clinical guidelines; improve safety and quality of care by engaging patients in the designing of 
processes and in better satisfaction with care114. Beyond that it is an ethical and legal obligation as 
patients need at least to be informed about their treatment. 
Subsequently it will be necessary to apply adequate and reliable tools that are reliable, valid and 
in line with the HRQL concept for the translation of the patient involvement into practice. Health-
related quality of life (HRQL) can be simply understood as how people are feeling. The basic 
question to ask then is whether the treatment will make the patient feeling better and whether the 
surrogate measures are adequate depends on how confident we are of the link with how people 
feel. These relationships are often modest and highly variable115; not so in haemodialysis treatment. 
The indicators chosen and discussed in 4.1.2 give a clear indication of the patients’ living quality 
and dialysis is a definite instrument to make the patients feel better. Nevertheless responsive, valid 
and interpretable instruments measuring experiences of importance to most patients on 
haemodialysis should increasingly help guide clinical decisions.  
But the participation of patients in the design of quality programmes is still not common 
practice as a even recent European quality assessment programme116 shows. This is most probably 
due to cultural differences between the US and Europe, as in the US powerful patient advocacy 
bodies defend patients’ interests. The European Kidney Patient’s Federation (CEAPIR) formulates 
in their quality programme for renal care in art. 5 that all renal patients have a right to be clearly and 
fully informed prior to all methods of treatment and that the choice of treatment must be in 
accordance with the patients’ own choice and medical condition117. A clear demand for quality 
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programmes however is not formulated. The Swiss kidney patient association (VNPS) which is a 
member of CEAPIR mentions in article 3118 that the dialysis treatment should be of utmost quality 
mentioning a few details of quality control measures that seem to be either common practice or 
slightly outdated. The author cannot withhold his impression that the patient places himself in a 
position of a health care receiver. There is no hint of the wish for an active participation in the 
medical care or care process at least in the documents mentioned. This may also explain the 
response of the organization that the questionnaire sent would be treated by their medical adviser. 
Another fact which is difficult to interpret is that all the consulted patient organizations are 
sponsored by the pharmaceutical industry.  
In view of the above and in view of the existence of several tools to measure patient 
preferences, patient satisfaction etc. it is proposed to evaluate first the knowledge of dialysis 
patients in Switzerland on their disease, treatment methods, patient rights and obligations linked to 
eventual better information provision. At the same time the SVK should take up the point of 
evaluation of “patient experience” as one of the areas for quality measuring in art. 5 of their 
contract with the providers as the case in the UK.  
Following the argumentation above it may be surprising that in the present study “patient 
criteria” or patient involvement has not been measured. Although judged of importance it would 
have exceeded the frame of the master thesis and it came by surprise that the patient organisation 
did not engage further that would have facilitated a better coverage of the viewpoint of the patient. 
5.4 IMPLEMENTATION MENU 
In the following implementation menu the existing reality as described in the preceding chapters 
has been taken into account. The lack of any control or reporting of quality in haemodialysis 
treatment and the lack of participation of the involved community (except the health insurer) in this 
study has bee described. Furthermore Swiss specific conditions, different from the neighbouring 
countries need to be considered. Switzerland is a federal country with strong local powers thus 
patients are used to finding full-fledged health care structure including dialysis facilities in all of the 
regions. This implies that the facilities are often small in size and that patients do not cross regional 
borders to seek treatment out of the canton. For this reason the quality evaluation needs to be 
applied nationwide to guarantee access to best care for most of the population, as patients will not 
behave competitive and look for best quality this even more so as transport is one of the key issues 
in patient comfort, and Switzerland being a mountainous country with long travel times in the rural 
areas. Competitive approaches can therefore be excluded.  
The proposed comprehensive information gathering could provide clinical data for numerous 
clinical questions in a relatively brief time frame, in contrast to more costly randomized clinical 
trials that address one question and take years to complete. This may render the data interesting for 
the public health field, the medical community, the insurer and the pharmaceutical industry thus 
assuring the financing of the implementation.  
5.4.1 Step plan (the dates in brackets are the dates of expected achievement)  
1. The SVK takes the initiative and asks an independent scientific institution specialised in 
health economics to prepare a quality evaluation tool (reporting sheet) based on this study 
with the help of an independent nephrologist – March 2006.  
2. The SVK presents the elaborated evaluation tool to its contractual partners within its regular 
commission meetings and makes the evaluation tool legally binding taking reference to article 
5 of the Swiss dialysis contract. – May 2006. 
3. The research institution (RI) makes contact with all participating clinical centres and contacts 
if needed the ethical commission – September 2006. 
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4. The data gathering begins and the first set of raw data is obtained from all centers - 
December 2006.  
5. Evaluation of the data – benchmarking – reporting to the institutions - June 2007 
In principle three different possibilities of benchmarking are possible within haemodialysis 
treatment; 
• defining the “best in class” as target value for all kinds of indicators on a world-wide or a 
national level 
• determining the national mean value as target for all kinds of indicators  
• determining the target values of chosen existing guidelines as target values for all kinds of 
indicators 
The reality in the medical field nearly imposes the option for the last version by passing as a first 
step through the determination of a mean on a national level. In a second step adherence to 
guideline targets should become the favoured option. Depending on the results observed in the 
centres, those with quality below average and below target values should be addressed by the SVK 
or the Swiss Society of Nephrology (SGN) in order to assist with quality improvement favouring an 
educational approach. The German experience has proven that simply the information on quality 
data was one of the keys to improvement. Therefore regulatory and financial interventions shall not 
be applied but may not be excluded. One option is to link the level of dialysis reimbursement to 
treatment quality on the condition that the impact on health effects is clearly demonstrated119.  
5.4.2 Implementation costs 
Implementation and running costs of quality control systems seem to be treated as a poor cousin in 
medical care. Even large quality systems do not evaluate or mention quality monitoring costs or the 
added financial burden for the providers, as Medicare120 and QiN shows. However, the average 
evaluation costs in QiN were roughly estimated to be in the range of 1-2 € (1.5 – 3 CHF) per 
dialysis121. 
As already said in chapter 4.1.2, the criteria proposed are routinely evaluated. Additional 
laboratory costs are therefore not to be expected. The data is generally available or easy to measure 
or to calculate. The fees for the presented reporting sheet were 40-100 CHF/patient/year, thus 
meaning that with an average of 70 CHF/patient/year x 3000 patients, the overall costs for filling 
out the formula can be estimated at 210.000 CHF/year born by the participating dialysis centres. If 
the German figure with an average of 2.25 CHF is applied the evaluation costs are approximately 1 
Mill. CHF. It has to be said however that the German system is a very complex and complicated 
system and that the investment needed for Switzerland is estimated at 600.000 CHF/year for the 
reason of its simplicity. Looking at the financial burden of 200 Mill. CHF for dialysis treatment 
each year a sufficient quality evaluation could be made for roughly 0.3% of the expenditure.  
This proposal has been elaborated by the author and has been judged realistic in its 
implementation schedule by a scientific institution experienced in this field, but it should be 
mentioned that the attributed roles were not discussed with the involved parties and chosen by the 
author. In this regard the resistance or the willingness to participate in the implementation may be 
difficult to estimate but the absolute silence of the Swiss Society of Nephrology (SGN) concerning 
the participation in this study may not be a very positive sign for their collaboration but the legal 
obligations are there and the advance of the neighbouring countries may exert a certain pressure 
too. 
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6. CONCLUSION 
This study answers one of the questions of what evidence based medicine is supposed to answer; it 
is best for the patient that a good and Swiss wide controlled quality system for haemodialysis 
treatment is installed under the condition that the patient is included as a partner in its development 
and implementation. The criteria chosen comply with the OECD criteria for indicators that are the 
impact on health, the policy importance and the susceptibility to the influence of the health care 
system. The second question on how to distribute health care resources is not answered in this 
study but indications are there that a good quality dialysis care reduces mortality, enhances living 
quality and may reduce associated costs of medication and the frequency and duration of 
hospitalizations. However a final judgment on the overall potential economic benefits or potential 
economic drawbacks cannot be made but should be evaluated in an economic evaluation.  
In view of  
• the legal obligation to control and improve quality, 
• the increasing demand and the increasing costs, 
• the potential gains in mortality reduction and improved living quality, 
• the eventual economic benefits, 
• the solid medical knowledge in this field,  
• the absence of national guidelines on dialysis treatment,  
• the difficulty in adherence to guidelines,  
• the non existence of published data on quality in dialysis treatment in Switzerland,  
• the highly regarded medical self-responsibility favoured by the different medical bodies,  
• the simplicity, the practicability, the reliability and validity of the proposed quality tool  
• the implementation facility and the low cost of the proposed quality tool, 
• and above all for the ethical responsibility for the severely ill patients on a life long 
treatment 
there is no time to lose to implement a system of quality care in haemodialysis treatment based 
on the model described and summarized in the table below; 
Finally this Master thesis may be taken as a “kick-off” event in order to do something tangible 
about quality in haemodialysis treatments or as in the words of the Swiss Medical Association 
(FMH) “Every physician has the ethical obligation to provide the best possible treatment to his 
patients”122.  Then, simply do it in a simple way. 
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TABLE 2: OUTLINE OF THE QUALITY EVALUATION TOOL 
CRITERIA TARGET VALUE, MEAN, TOOL OR INFORMATION SOURCE 
GENDER RATIO MALE/FEMALE MEAN 
AGE RANGE MEAN 
ATTENDANCE IN % 100 
HB (G/DL) ≥ 11 
BMI (KG/M2) - 
CA X PO4 MMOL2/L2 ≤ 4.44 
KT/V SINGLE POOL ≥ 1.4 
PREDIALYSIS SYST. BP (MMHG) 130 
PREDIALYSIS DIAST. BP (MMHG) 80 
VASCULAR ACCESS MEDICAL HISTORY FILE  
INFLAMMATION MEDICAL HISTORY FILE 
HOSPITALIZATIONS/YEAR MEDICAL HISTORY FILE 
HOSPITALIZATION DURATION MEDICAL HISTORY FILE 
QUALITY OF LIFE EVALUATION TOOL SUCH AS QUESTIONNAIRE 
RISK ADJUSETEMENT (CASE-MX) AGE, DIABETES, IN-PATIENT, EVENT. GENDER AND OTHERS 
PATIENT KNOWLEDGE AND PATIENT 
PARTICIPATION 
INTERVIEWS, QUESTIONNAIRES, EDUCATIONAL 
PROGRAMMES 
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Annex 1 
Dr. Jörg Spieldenner 
Ch. de la Borgnette 
1965 Ormône/Savièse 
 
Herr Direktor 
Name 
Address 
 
 
12. November 2005 
BETR.: QUALITÄTSMANAGEMENTSTUDIE DIALYSE 
Sehr geehrter Herr X, 
wie ich von meinem geschätzten Kollegen, Herrn Dr. XX in der Klinik XXX erfahren 
habe, ist die XXXXgruppe sehr am Qualitätsmanagement interessiert wie von Ihrem 
Kollegen Herrn XXXXX bestätigt wurde (Brief im Anhang).  
 
Ich möchte Sie deshalb bitten wollen, im Rahmen meiner Master Arbeit in 
Gesundheitsökonomie und Gesundheitsmanagement der Universität Lausanne auf 
anonymisierte klinische Laborwerte von Patienten der Hämodialysestation zugreifen zu 
dürfen. Es handelt sich hier um eine Studie zum Qualitätsmanagement der 
Hämodialysebehandlung. Einen Überblick der Studie finden Sie im Anhang.  
 
Ich würde mich über einen kurzfristigen positiven Bescheid Ihrerseits sehr freuen und 
stehe jederzeit für weitere Auskünfte gerne bereit 
 
Mit freundlichen Grüssen 
 
Jörg Spieldenner 
Anlage (2) 
 
  
 
Annex 2 
Outline of the Master thesis within the Post graduate course – “Master in 
Health Economics and Management” of the Institut d’économie et 
management de la santé of the University of Lausanne  
 
QUALITY EVALUATION IN HAEMODIALYSIS TREATMENT 
THROUGH “BENCHMARKING” – A MEDICAL AND ECONOMICAL 
OUTLOOK 
INTRODUCTION: 
 
Medical quality is a controversially discussed subject in Swiss and international health policy over 
the last years. Service providers such as medical doctors, payers such as insurers and health 
authorities have an interest in demonstrating efficiency and efficacy of medical care and medical 
treatment methods. Each group has different interests but the main aim is similar - providing good 
quality health care at bearable costs to most of the citizens. Nevertheless concise and applicable 
medical quality criteria are scarcely developed and even less so put into practice. 
 
This is not different in the treatment of renal pathologies that require dialysis. (Only haemodialysis 
is being considered as this treatment is the most common dialysis therapy) Despite the fact that in 
article 4 and 5 of the contract between provider and insurer (Dialyse Vertrag SVK) clear reference 
is given to the principle of economicity and quality, agreed upon quality criteria of the dialysis 
treatment do not yet exist on national level. 
 
But why is quality in dialysis treatment so important? In view of an aging population, the demand 
for dialysis treatment will sour in the coming years. Patients receiving this type of treatment are in 
general chronically ill, often on life-long treatment and with multiple associated pathologies. Their 
general health state and their living quality depend essentially on the quality of the dialysis 
treatment.  
 
Beyond these medical considerations economic considerations are to be taken into account. 
According to the data of the SVK (Schweizerischer Verband für Gemeinschaftsausgaben der 
Krankenversicherer) 3730 patients received dialysis treatment in 2003 that generated costs of 
approximately 173 Mill.CHF. Most of these costs are caused by haemodialysis, each patient costing 
on average approximately 77000 CHF a year. The costs for the treatment of associated pathologies 
and the costs for the drugs needed for the dialysis are not reflected in these figures whereas a good 
quality dialysis has an impact on associated pathologies and the amount and type of medication 
needed.  
 
In view of the above said it becomes evident that the dialysis treatment should be given priority in 
the development of applicable national quality criteria in particular as the proposed medical criteria 
are evaluated and available in the dialysis centres and as the SVK alone has access to data of 5.9 
Million insured clients for this type of therapy.  
 
  
 
 
PROCEDURE AND METHODOLOGY: 
 
In the first part clinical, easily available and measurable parameters will be discussed that give a 
concise idea on the quality of the dialysis treatment. These parameters are Urea Reduction Ratio, 
Kt/V (dialysis efficacy), amount of haemoglobin, erythropoietin-dose (control of anaemia); 
albumin, protein catabolic rate, body mass index (control of malnutrition), calcium phosphorus 
product and parathormones (control of calcium phosphorus balance) pre- and postdialytic blood 
pressure and some demographic data.  
 
This will be followed by an assessment of clinical data (retrospective) from some clinical dialysis 
centres. These data will be used to demonstrate the practical application of the quality model and to 
give an indication for the Benchmarking.  
 
In the second part we will be looking at possible economical mechanisms with the aim to improve 
the medical quality of the dialysis treatment. Attention will be paid to practical economic tools and 
the possible impact on the overall costs of the dialysis treatment.  
 
The research will be concluded by a critical outlook and the possibility of implementation of such a 
model.   
 
 
Director of the thesis:  Prof. Gianfranco Domenighetti 
 
  
Annex 3 
 
Monthly reporting sheet of hemodialysis patients  
              Hemodialysis Centre     Code      
      
            Month November   Year 2005       
      
                  
Patient Sex 
Age 
Range
* 
Attendance 
in %** 
Hb 
(g/dl) 
EPO 
Dose*** 
(units) 
EPO/KG BMI (kg/m2) 
Ca x PO4 
(mmol2/l2) 
PTH 
(pmol/l) 
kt/V 
single 
pool 
URR 
(%) 
nPCR 
(g/kg/day) 
Albumin 
(g/l) 
Predialysis 
syst. BP 
(mmHg) 
Predialysis 
diast. BP 
(mmHg) 
Postdialysis 
syst. BP 
(mmHg) 
Postdialysis 
diast. BP 
(mmHg) 
1                  
2                  
3                  
4                  
5                  
6                  
7                  
8                  
9                  
10                  
11                  
12                  
13                  
14                  
15                  
16                  
17                  
                             
mean                   
STD                   
median                   
            
      
*Age range                  
1 - <18 2 - 18 - 44 3 - 45 - 59 4 - 60 - 69 5 - 70 - 79 6 - ≥ 80 
    
      
            
      
**Attendance                 
attendended hemodialysis treatments/planned hemodialysis treatments            
            
      
*** EPO E/week: recalculated in case of Aranesp application (correction factor 200)           
            
      
            
      
            
      
            
      
  
Annex 4 
Fragenkatalog an die X im Rahmen des Master of health economics 
and management der Universität Lausanne 
 
1. Ist die X an einer Qualitätsevaluierung und einer Qualitätssteigerung der Dialysebehandlung in 
der Schweiz interessiert?  
 
2. Wenn ja was plant oder tut die X oder die Y um die Qualität der Dialysebehandlung und hier 
insbesondere um die der Hämodialysebehandlung zu evaluieren und zu sichern? 
 
3. Hat die X oder die Y „practice guidelines“ zur Dialysebehandlung entwickelt oder empfiehlt sie 
die Anwendung von practice guidelines und wenn ja welche (K/DOQI, European etc.)?  
 
4. Gibt es Ihres Wissens nach Studien oder Untersuchungen, die den Zusammenhang von 
Dialysebehandlung, Qualität und ökonomischen Daten in der Schweiz untersucht haben? 
Können Sie hier welche nennen? 
 
5. Gibt es in der Schweiz andere Adressen oder Institutionen die gesammelt Daten zur 
Dialysebehandlung entweder besitzen oder sogar aktiv erheben, z.B. nationales Register 
 
6. Gibt es nach Meinung der X oder der Y Zugangshürden, die die langdauernde Dialysebehandlung 
erschweren oder unmöglich machen, so z.B. Alter, Krankheiten oder mangelnde 
Dialysekapazitäten?  
 
7. Kann ein Dialysepatient frei zwischen verschiedenen Dialysezentren wählen, also auch 
ausserkantonal gehen, selbst wenn innerkantonal ein ausreichendes Angebot besteht? 
 
8. Werden Daten erhoben, die Aussagen über die Patientenzufriedenheit und Dialysequalität 
ermöglichen? 
 
9. Wie und durch wen werden Dialysezentren- praxen akkreditiert?  
 
10. Hat die X Einsicht in die Abrechnungsdaten aller dialysierten Patienten in der Schweiz oder nur 
in die Daten der von ihr abgerechneten Patienten?  
 
11. Sollte die X nur Daten der über sie abgerechneten Patienten besitzen, kann die X in etwa schätzen 
welcher Prozentsatz aller Dialysen ausserhalb des Abrechnungssystems der X abgerechnet wird 
und wie viele Patienten das in etwa betrifft?   
 
12. Wie viele Patienten befinden sich zurzeit in einer Dialysebehandlung und wie hat sich diese Zahl 
in den letzten Jahren entwickelt? Wie sehen sie die weitere Entwicklung/Zunahmen? Haben sie 
Schätzungen dazu? - bitte hier aktuelle Inzidenz/Prävalenzzahlen  
 
13. Wie viele Dialysezentren gibt es in der Schweiz und welche Anzahl von Patienten behandelt jedes 
Dialysezentrum (hier wenn möglich Tabelle)  
 
14. Wie ist die prozentuale Verteilung von Peritonealdialyse und Hämodialyse jeweils nach Zentrums- 
sowie Heimdialyse getrennt? 
 
15. Wie viele Patienten befinden sich in Hämodialysebehandlung und wie viele davon in 
Hämodialysezentren? (Ratio Heim/Zentrumsdialyse (auch Prozentsätze möglich)? 
 
16. In welchem Zeitrahmen rechnet die X mit den Leistungserbringern ab (monatlich, vierteljährlich, 
halbjährlich, jährlich)? 
  
 
17. Erhebt die X oder hat die X Erkenntnisse über die Gesamtkosten eines Dialysepatienten, z.B. 
über medikamentöse Kosten (Erythropoetin etc.) sowie über die Behandlungskosten für 
Begleiterkrankungen ? Wenn ja, kann die X einen Durchschnittswert für diese Kosten pro 
Hämodialysepatienten angeben, auch Schätzung möglich?  
 
18. Erhebt die X oder hat die X Zugang zu Qualitätsdaten der Dialysebehandlung wie z.B. 
Mortalitätsstatistiken, life years gained etc.?  
 
19. Durchschnittliche Überlebensrate , z.B. 1-Jahres Mortalität der Hämodialysepatienten und/oder 
aller Dialysepatienten in der Schweiz? 
 
20. Wie lange bleibt ein Patient durchschnittlich in Hämodialysebehandlung und/oder 
Dialysebehandlung? 
  
 
Annex 5 
Dr. Jörg Spieldenner 
Ch. de la Borgnette 
1965 Ormône/Savièse 
spieldenner@web.de 
 
Name 
Address 
 
12. Dezember 2005 
BETR.: QUALITÄTSEVALUATION DIALYSE 
Sehr geehrter Herr X, 
im Rahmen meines postgradualen Masterstudienganges in Gesundheitsökonomie und 
Gesundheitsmanagement der Universität Lausanne habe ich das Thema Qualität in der 
Hämodialysebehandlung als Abschlussarbeit gewählt.  
 
Im Rahmen dessen möchte ich Sie bitten, mir den beigefügten Fragenkatalog soweit als 
möglich bis spätestens 15.1.06 zu beantworten und mir allfällige Unterlagen zu senden. Es 
bleibt selbstverständlich Ihnen überlassen auf welche Fragen sie antworten wollen und 
können. Dazu kann ich Ihnen selbstverständlich auch das Dokument als e-mail senden wenn 
sie dies wünschen. Einen Überblick der Studie finden Sie im Anhang.  
 
Ich möchte mich bereits im voraus für Ihre Mitarbeit bedanken und sehe den von Ihnen 
gesandten Informationen mit Interesse entgegen, stehe jederzeit für weitere Auskünfte gerne 
bereit und verbleibe  
 
mit freundlichen Grüssen 
 
Jörg Spieldenner 
 
Anlage (2) 
  
 
 
 
Annex 6 
Recherche effectuée pour Dr Jörg Spieldenner  16.11.05 & 24.11.05/ tbr  
« 1. Stratégie de recherche Medline = Pubmed 
www.pubmed.gov 
Database: Ovid MEDLINE(R) <1966 to November Week 3 2005> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     kidney disease outcomes quality initiative.ti. (8) 
2     Renal Dialysis/ (50876) 
3     Renal Dialysis/ec (852) 
4     exp "Quality of Health Care"/ (2674802) 
5     BENCHMARKING/ (4480) 
6     2 and 4 (13808) 
7     3 and 4 (350) 
8     2 and 5 (15) 
9     *Renal Dialysis/ (33475) 
10     *renal dialysis/ec (373) 
11     Renal Dialysis/sn, ut [Statistics & Numerical Data, Utilization] (898) 
12     SWITZERLAND/ (18378) 
13     exp EUROPE/ (721012) 
14     11 and 12 (3) 
15     11 and 13 (253) 
16     limit 15 to yr="1998 - 2005" (144) 
17     limit 16 to yr="2000 - 2005" (107) 
18     *Renal Dialysis/sn, ut (392) 
19     17 and 18 (57) 
20     from 19 keep 1,9,23,29,43,55 (6) 
21     5 and 10 (0) 
22     3 and 10 (373) 
23     10 and 4 (118) 
24     exp *quality of health care/ (298024) 
25     10 and 24 (18) 
26     from 25 keep 1-3,6,8-9,11,13,16 (9) 
27     *health policy/ (16266) 
28     24 and 27 (1171) 
29     limit 28 to "review articles" (183) 
30     2 and 29 (0) 
31     2 and 28 (2) 
32     from 31 keep 1 (1) 
33     doqi.mp. (328) 
34     2 and 33 (178) 
35     doqi.ti. (99) 
36     1 or 35 (102) 
37     2 and 36 (54) 
38     from 37 keep 2,9-11,13,16,18,20,46 (9) 
39     20 or 26 or 32 or 38 (25) 
40     "Quality of Life"/ (49768) 
41     *Patient Satisfaction/ (9071) 
42     9 and 40 (654) 
 
  
43     *quality of life/ (21294) 
44     9 and 43 (317) 
45     9 and 41 (35) 
46     limit 45 to yr="2000 - 2005" (20) 
47     from 46 keep 1-2,4-6,11,13,15-16,18 (10) 
48     from 47 keep 1-10 (10) 
2. Recherche dans la base de données SCOPUS 
www.scopus.com 
(TITLE-ABS-KEY(k/doqi) AND TITLE-ABS-KEY(haemodialysis))  
(TITLE-ABS-KEY(swiss) AND TITLE-ABS-KEY(haemodialysis) 
(TITLE-ABS-KEY(switzerland) AND TITLE-ABS-KEY(haemodialysis) 
(TITLE(economic) AND TITLE-ABS-KEY(haemodialysis))  
3. Recherche dans la Banque de données Santé Publique 
http://www.bdsp.tm.fr/ 
Faites une recherche « tous champs » 
mcl=qualite AND mcl=hemodialyse 
4. Recherche dans le catalogue Saphir 
www.saphirdoc.ch 
Recherche  Recherche avancée 
Descripteurs MeSH : Renal Dialysis » 
  
Annex 7A 
 
Monthly reporting sheet of hemodialysis patients  
              Hemodialysis Centre  Y   Code 1     
      
            Month November   Year 2005       
      
                  
Patient Sex 
Age 
Range
* 
Attendance 
in %** 
Hb 
(g/dl) 
EPO 
Dose***(u
nits) 
EPO/KG BMI (kg/m2) 
Ca x PO4 
mmol2/l2) 
PTH 
(pmol/l) 
kt/V 
single 
pool 
URR 
(%) 
nPCR 
(g/kg/day) 
Albumin 
(g/l) 
Predialysis 
syst. BP 
(mmHg) 
Predialysis 
diast. BP 
(mmHG) 
Postdialysis 
syst. BP 
(mmHG 
Postdialysis 
diast. BP 
(mmHG 
1 M 4 100 12.7 12'000 130.4 32 4.59 2.5 1.54 74.2 1.11 39 172 70 128 67 
2 F 5 100 11.9 8'000 86.9 35 2.34 7.2 1.31 67.0 0.84 34 125 70 145 57 
3 M 5 100 12.6 5'000 68.0 26 3.51 16.1 1.82 79.0 0.9 41 161 77 144 69 
4 F 4 100 11.2 10'000 238.0 19 2.85 8.6 1.26 70.0 0.79 27 150 80 130 80 
5 F 5 100 13.2 18'000 288.0 25 4.67 14.2 1.63 78.0 1.12 40 170 83 168 80 
6 M 5 100 11.0 4'000 67.2 23 2.37 6.9 2.15 80.0 1.23 35 180 85 105 60 
7 M 4 100 12.0 8'000 98.8 28 3.02 5.5 1.75 79.0 1.1 36 137 80 111 64 
8 M 3 100 12.9 6'000 78.4 24 4.31 11.2 1.61 74.8 1.07 43 120 75 120 80 
9 M 5 100 11.0 24'000 342.9 21 2.37 16.1 1.51 68.0 1.23 28 175 85 115 60 
10 M 4 100 11.5 6'000 70.9 27 3.92 40.3 1.9 79.5 1.02 38 165 85 130 80 
11 F 5 100 10.9 4'000 85.1 15 2.74 7.3 1.98 83.0 1.25 38 140 75 150 80 
12 F 5 100 13.0 1'500 26.3 21 4.5 16.7 1.77 83.0 0.78 39 138 56 171 71 
13 M 4 100 11.0 5'000 87.0 21 4.35 16.2 2.24 84.0 1.13 38 175 92 114 83 
14 M 3 100 11.9 2'000 26.8 21 4.25 22.0 1.47 73.7 1.03 45 157 89 186 99 
15 F 4 100 10.7 12'000 157.9 31 3.24 11.4 2.18 84.0 1.02 33 160 82 138 67 
16 M 2 100 11.5 16'000 293.6 19 3.68 23.0 2.21 84.6 1.1 35 121 82 117 79 
17 M 5 100 12.0 6'000 61.2 30 4.14 12.7 1.23 68.0 1 40 113 60 116 55 
                                    
mean   4.24 100 11.8 8'676 129.8 24.6 3.58 14.0 1.74 77.0 1.04 37.0 151 78 135 72 
STD   0.90 0 0.8 6065 98.8 5.4 0.84 8.8 0.33 6.1 0.14 4.7 22 10 23 12 
median   4.00 100 11.9 6'000 86.9 24.0 3.68 12.7 1.75 79.0 1.07 38.0 157 80 130 71 
            
      
*Age range               
1 - <18 2 - 18 - 44 3 - 45 - 59 
 
4 - 60 - 69 5 - 70 - 79 6 - ≥ 80 
       
               
**Attendance               
attendended hemodialysis treatments/planned hemodialysis treatments          
               
*** EPO E/week: recalculated in case of Aranesp application (correction factor 200)         
Eprex  3             
Recormon  8             
Aranesp  6             
Sum  17             
  
Annex 7B 
 
Monthly reporting sheet of hemodialysis patients  
              Hemodialysis Centre  Y   Code 2     
      
            Month November   Year 2005       
      
                  
Patient Sex 
Age 
Range
* 
Attendance 
in %** 
Hb 
(g/dl) 
EPO 
Dose***(u
nits) 
EPO/KG BMI (kg/m2) 
Ca x PO4 
(mmol2/l2) 
PTH 
(pmol/l) 
kt/V 
single 
pool 
URR 
(%) 
nPCR 
(g/kg/day) 
Albumin 
(g/l) 
Predialysis 
syst. BP 
(mmHg) 
Predialysis 
diast. BP 
(mmHg) 
Postdialysis 
syst. BP 
(mmHg) 
Postdialysis 
diast. BP 
(mmHg) 
1 m 6 100 13.3 2'000 25.0 27 3.99 14.8 1.2 66.0 0.73 38 154 79 153 85 
2 f 5 100 13.5 12'000 203.0 22 4.66 1.4 1.39 70.0 0.99 39 212 85 171 79 
3 f 6 100 12.3 6'000 118.0 19 2.94 1.3 1.33 69.0 0.67 30 144 77 196 91 
4 m 5 100 12.4 4'000 60.0 24 3.15 39.9 1.1 60.0 1.24 37 186 99 148 83 
5 m 5 100 13.6 4'000 74.0 20 4.93 1.2 1.57 77.0 1.67 34 175 63 138 61 
6 m 5 100 12.7 6'000 120.0 18 2.34 - 1.57 75.0 1.18 31 109 69 115 71 
7 m 6 100 14.3 - - 27 5.39 147.9 1.43 71.0 1.34 39 132 76 113 59 
8 m 5 100 12.6 - - 23 4.34 52.1 1.47 71.0 1.3 38 235 112 190 101 
9 m 5 100 11.8 6'000 86.0 22 5.16 12.6 1.37 69.0 1.2 42 158 73 171 78 
10 f 5 100 15.1 6'000 136.0 19 4.21 1.0 2.1 83.0 1.46 36 84 49 86 55 
11 f 3 100 11.4 6'000 115.0 18 4.42 6.4 1.62 75.0 1.12 38 164 89 151 86 
12 m 2 100 10.9 12'000 162.0 24 5.36 18.7 1.04 57.0 1.08 42 190 101 148 80 
13 m 5 100 13.2 4'000 56.0 26 4.72 96.3 1.44 71.0 1.36 40 131 74 113 68 
14 m 5 100 11.2 6'000 92.0 21 3.37 21.9 1.14 64.0 0.99 36 169 73 137 60 
15 m 5 100 11.6 9'000 120.0 21 3.51 13.3 1.1 63.0 0.78 37 152 79 202 95 
16 f 5 100 11.8 6'000 92.0 23 6.16 - 1.93 81.0 1.54 - 179 84 142 81 
17 f 5 100 12.2 9'000 180.0 21 4.98 - - - - - 164 103 156 97 
                                    
mean   4.9 100 12.6 6'533 109.3 22.1 4.33 30.6 1.43 70.1 1.17 37.1 161 81 149 78 
STD   1.0 0 1.1 2850 48.1 2.9 1.01 42.7 0.29 7.1 0.29 3.4 36 16 31 14 
median   5.0 100 12.4 6'000 115.0 22.0 4.42 14.1 1.41 70.5 1.19 38.0 164 79 148 80 
            
      
*Age range               
1 - <18 2 - 18 - 44 3 - 45 - 59 
 
4 - 60 - 69 5 - 70 - 79 6 - ≥ 80 
       
               
**Attendance               
attendended hemodialysis treatments/planned hemodialysis treatments          
               
*** EPO E/week: recalculated in case of Aranesp application (correction factor 200)         
Eprex  1             
Recormon  15             
Aranesp  1             
Sum  17             
 
